WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD.Can-Fite BioPharma Ltd. • January 10th, 2020 • Pharmaceutical preparations • New York
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January ___, 2020 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ____________________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Can-Fite BioPharma Ltd., an Israeli limited company (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by ________2 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • January 10th, 2020 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of January 9, 2020, is by and between Can-Fite BioPharma Ltd., an Israeli company (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase ordinary shares of the Company, par value NIS 0.25 per share (the “Ordinary Shares”), represented by American Depositary Shares issued by the Company, which warrants were issued in September 2015, October 2015, March 2018, January 2019 and April 2019 and are exercisable at an exercise price of $78.75 per ADS, $78.75 per ADS, $30.00 per ADS, $19.50 per ADS and $12.90 per ADS, respectively (the “Original Warrants”).
